BioNTech erweitert fortgeschrittenes klinisches Onkologie-Portfolio: Weiterer Phase-2-Studienstart mit mRNA-basierter individualisierter Neoantigen-spezifischer Immuntherapie in neuer Krebsindikation
October 19, 2023 06:45 ET
|
BioNTech SE
Grundlage für Phase-2-Studienstart waren Daten einer klinischen Phase-1-Studie zur Untersuchung der Sicherheit und Verträglichkeit von Autogene Cevumeran (BNT122, RO7198457) in Kombination mit...
BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication
October 19, 2023 06:45 ET
|
BioNTech SE
Initiation of Phase 2 builds on data from a Phase 1 clinical trial evaluating the safety and tolerability of autogene cevumeran (BNT122, RO7198457) in combination with the anti-PD-L1 immune checkpoint...
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
September 27, 2023 08:00 ET
|
Vaccinex, Inc.
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be reviewed on September 28 at CHI's 20th Annual Discovery on...
Government’s Critical Minerals Strategy Recognizes Canada’s Once-in-a-Generation Opportunity to Lead Low Carbon Transition
December 09, 2022 13:30 ET
|
Prospectors & Developers Association of Canada (PDAC)
VANCOUVER, British Columbia, Dec. 09, 2022 (GLOBE NEWSWIRE) -- The Prospectors & Developers Association of Canada (PDAC) is encouraged to see its recommendations on behalf of Canada’s mineral...
Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results
November 21, 2022 09:00 ET
|
Oncotelic Therapeutics, Inc.
R&D cost reduced in excess of 95% while continuing expansion of our OT-101 clinical programs through our joint ventureG&A cost reduced by approximately 50%Net loss reduced by approximately...
Oncotelic Publishes SITC Meeting 2022 Presentation Materials
November 16, 2022 08:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications,...
LICY FINAL DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. Investors to Secure Counsel Before Important June 21 Deadline in Securities Class Action Filed by the Firm – LICY, PDAC
June 19, 2022 13:00 ET
|
The Rosen Law Firm PA
NEW YORK, June 19, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp....
LICY FINAL DEADLINE ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. Investors with Losses to Secure Counsel Before Important June 20 Deadline in Securities Class Action Filed by the Firm – LICY, PDAC
June 13, 2022 16:45 ET
|
The Rosen Law Firm PA
NEW YORK, June 13, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp....
Atlas Drills Another Large Step-Out at Great Atlantic
June 10, 2022 10:16 ET
|
Atlas Salt Inc.
ST. JOHN’S, Newfoundland and Labrador, June 10, 2022 (GLOBE NEWSWIRE) -- Atlas Salt (the “Company” or “Atlas” - TSXV: SALT) is pleased to report that as the Company progresses toward completion of...
South Grass Valley Carlin-Type Gold Project – June 2022 Update
June 09, 2022 09:00 ET
|
Nevada Exploration Inc.
RENO, Nev., June 09, 2022 (GLOBE NEWSWIRE) -- Highlights: Drillhole SGVC014 stopped at 534 metres due to lost tooling, being redrilled as SGVC014A, and now at 640 metres.Features of...